Medtronic plc (MDT) Debt to Equity Ratio: 0.00
Is Medtronic plc’s debt to equity ratio high or low?
Medtronic plc's debt to equity ratio of 0.00 is 100% below its 5-year average of 0.42, near the low end of its 5-year range (0.00–0.59).
The debt to equity ratio for Medtronic plc (MDT) is 0.00 as of Tuesday, June 9, 2026. It is below its 12-month average by 100.00% (0.29).
MDT Debt to Equity Ratio Chart
MDT Average Debt to Equity Ratio Chart
MDT Current vs Average Debt to Equity Ratio Chart
MDT Debt to Equity Ratio Metrics
DEBT TO EQUITY RATIO
0.00
DEBT TO EQUITY RATIO AVG TTM
0.29
DEBT TO EQUITY RATIO AVG 3Y
0.39
DEBT TO EQUITY RATIO AVG 5Y
0.42
DEBT TO EQUITY RATIO AVG 10Y
0.48
DEBT TO EQUITY RATIO AVG 15Y
0.52
DEBT TO EQUITY RATIO AVG 20Y
0.55
CURRENT VS TTM AVG
-100.00%
CURRENT VS 3Y AVG
-100.00%
CURRENT VS 5Y AVG
-100.00%
CURRENT VS 10Y AVG
-100.00%
CURRENT VS 15Y AVG
-100.00%
CURRENT VS 20Y AVG
-100.00%
MDT Competitors' Debt to Equity Ratio
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Medtronic plc (MDT) | — | 0.00 | 0.29 | 0.39 | 0.42 |
| Vertex Pharmaceuticals Incorporated (VRTX) | $113.14B | 0.21 | 0.16 | 0.11 | 0.11 |
| Bristol-Myers Squibb Company (BMY) | $115.34B | 2.55 | 2.84 | 2.10 | 1.84 |
| Elevance Health Inc. (ELV) | $92.17B | 0.76 | 0.78 | 0.74 | 0.71 |
| CVS Health Corporation (CVS) | $123.84B | 1.24 | 1.17 | 1.09 | 1.10 |
| Cigna Corporation (CI) | $78.04B | 0.75 | 0.77 | 0.73 | 0.72 |
| Danaher Corporation (DHR) | $133.37B | 0.35 | 0.35 | 0.37 | 0.43 |
| Pfizer Inc. (PFE) | $146.48B | 0.78 | 0.77 | 0.68 | 0.63 |
| Regeneron Pharmaceuticals, Inc. (REGN) | $63.48B | 0.09 | 0.09 | 0.10 | 0.13 |
| Intuitive Surgical, Inc. (ISRG) | $151.09B | 0.02 | 0.01 | 0.01 | 0.01 |
Financial Health
Debt/Equity
0.00
Current Ratio
0.00
Medtronic plc Debt to Equity Ratio Formula & Definition
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Medtronic plc Debt to Equity Ratio FAQ
- What is the debt to equity ratio for Medtronic plc (MDT)?
- The debt to equity ratio for MDT stock is 0.00.
- Is Medtronic plc's debt to equity ratio high or low?
- Medtronic plc's debt to equity ratio of 0.00 is 100% below its 5-year average of 0.42, near the low end of its 5-year range (0.00–0.59).
- What is the TTM average debt to equity ratio for Medtronic plc (MDT)?
- The TTM average debt to equity ratio for MDT stock is 0.29.
- What is the 3Y average debt to equity ratio for Medtronic plc (MDT)?
- The 3Y average debt to equity ratio for MDT stock is 0.39.
- What is the 5Y average debt to equity ratio for Medtronic plc (MDT)?
- The 5Y average debt to equity ratio for MDT stock is 0.42.
- What is the 10Y average debt to equity ratio for Medtronic plc (MDT)?
- The 10Y average debt to equity ratio for MDT stock is 0.48.
- What is the 15Y average debt to equity ratio for Medtronic plc (MDT)?
- The 15Y average debt to equity ratio for MDT stock is 0.52.
- What is the 20Y average debt to equity ratio for Medtronic plc (MDT)?
- The 20Y average debt to equity ratio for MDT stock is 0.55.
Medtronic plc Debt to Equity Ratio History
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-04-24 | 0.00 |
| 2025-04-25 | 0.59 |
| 2024-04-26 | 0.50 |
| 2023-04-28 | 0.47 |
| 2022-04-29 | 0.46 |
| 2021-04-30 | 0.51 |
| 2020-04-24 | 0.49 |
| 2019-04-30 | 0.51 |
| 2018-04-30 | 0.51 |
| 2017-04-30 | 0.66 |
| 2016-04-30 | 0.60 |
| 2015-04-30 | 0.68 |
| 2014-04-30 | 0.61 |
| 2013-04-30 | 0.57 |
| 2012-04-30 | 0.61 |
| 2011-04-30 | 0.60 |
| 2010-04-30 | 0.65 |
| 2009-04-30 | 0.53 |
| 2008-04-30 | 0.60 |
| 2007-04-30 | 0.55 |
| 2006-04-30 | 0.84 |
| 2005-04-30 | 0.23 |
| 2004-04-30 | 0.26 |
| 2003-04-30 | 0.30 |
| 2002-04-30 | 0.39 |
| 2001-04-30 | 0.03 |
| 2000-04-30 | 0.07 |
| 1999-04-30 | 0.07 |
| 1998-04-30 | 0.09 |
| 1997-04-30 | 0.07 |
Related Metrics
About Medtronic plc
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Geoffrey Straub Martha